{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 144 of 169', 'E-mail address: clinical_trial_jp@leo-pharma.com', 'Note: reports sent to the above fax number and email address will automatically be', 'forwarded to Global Pharmacovigilance, LEO.', 'Section 11.3.2 LEO reporting responsibilities', 'Global Pharmacovigilance, LEO will notify the regulatory authorities and concerned', 'investigators of SAEs according to the current applicable legislation for the concerned', 'countries.', 'In Japan, Pharmacovigilance, LEO Pharma K.K. will be responsible for notifying the', 'regulatory authorities and concerned investigators of SAEs.', 'Section 11.4.1 Pregnancy', 'Any pregnancy occurring during the clinical trial must be reported to LEO within 24 hours of', 'first knowledge using the (paper) Pregnancy Follow Up Form (Part I). All such pregnancies', 'must be followed up until delivery or termination and final outcome must be reported on the', '(paper) Pregnancy Follow Up Form (Part II) within 24 hours of first knowledge.', 'The completed Pregnancy Follow Up Forms must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO.', 'In Japan, any pregnancy must be reported to Pharmacovigilance, LEO K.K. using the', 'contact information below:', 'Fax number: +81 3 4243 3311', 'E-mail address: clinical_trial_jp@leo-pharma.com', 'Note: reports sent to the above fax number and email address will automatically be', 'forwarded to Global Pharmacovigilance, LEO.', 'Appendix 4A: Regulatory and ethical considerations', 'The protocol, protocol amendments, subject information leaflet including the informed', \"consent form (ICF), Investigator's Brochure, and other relevant documents (for example\", 'advertisements) must be submitted to an IRB/IEC by the investigator (...).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 145 of 169', 'In Japan, the documents will be submitted to the IRB/IEC by the sponsor (LEO', 'Pharma K.K.).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 146 of 169', 'Appendix 8: Contact list', 'Contact list of LEO, protocol authors, vendors, and trial committees', \"Contact details for the clinical project manager, national lead CRA (NLCRA), and sponsor's\", 'medical expert are provided to the trial sites as a separate contact list.', 'Sponsor', 'LEO Pharma A/S (referred to as \\'LEO\\' or \"the sponsor\\' in this clinical trial protocol) is the', 'sponsor of the clinical trial:', 'LEO Pharma A/S', 'Industriparken 55', 'DK-2750 Ballerup', 'Denmark', 'LEO Pharma K.K. is the sponsor of the clinical trial in Japan on behalf of LEO Pharma A/S:', 'LEO Pharma K.K.', '3-11-6 Iwamotocho', 'Chiyoda-ku', 'Tokyo 101-0032', 'Japan', 'Protocol authors', 'Andreas Wollenberg, Prof. Dr. med. Dr. h.c., International coordinating investigator,', 'Department of Dermatology and Allergy, Ludwig-Maximilian University Munich, Germany', 'PPD', ', M.Sc. Stat, Principal Statistician, LEO Pharma A/S, Denmark', 'PPD', '\"', 'MD, Senior Global Medical Science Lead, LEO Pharma A/S, Denmark', 'PPD', ', PhD, Senior Principal Scientific Advisor, LEO Pharma A/S, Denmark', 'PPD', ', MD, Senior PV Advisor, LEO Pharma A/S, Denmark', 'PPD', ', M.Sc. Pharm, Clinical Project Manager, LEO Pharma A/S, Denmark', 'PPD', ', PhD, Medical Communication Scientist, LEO Pharma A/S, Denmark', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}